Akero Therapeutics (AKRO) Stock Price, News & Analysis

Company Overview

Akero Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing novel therapies for severe metabolic diseases, with an initial emphasis on nonalcoholic steatohepatitis (NASH). The company’s research platform leverages engineered versions of endocrine hormones to target key pathways involved in lipid metabolism, glucose regulation and tissue fibrosis. By harnessing the biology of fibroblast growth factor 21 (FGF21), Akero aims to address underlying drivers of metabolic dysfunction rather than merely treating symptoms.

The company’s lead product candidate, efruxifermin, is an Fc-FGF21 fusion protein designed to improve liver health and metabolic parameters in patients with NASH. Efruxifermin has demonstrated reductions in liver fat content, improvements in markers of liver injury and favorable changes in lipid and glucose profiles in early-phase clinical studies. Akero is advancing efruxifermin through pivotal trials, including global Phase 2 and Phase 3 studies, with the goal of achieving regulatory approval for patients with advanced liver fibrosis due to NASH.

Founded in 2017 and headquartered in Boston, Massachusetts, Akero Therapeutics operates research and development facilities in North America while engaging clinical sites across the United States and Europe. The company’s scientific leadership comprises experts in metabolic disease biology, protein engineering and drug development, supported by advisory collaborations with leading academic institutions. Akero’s board includes seasoned biotech investors and executives who guide its strategic direction.

In addition to its lead program, Akero is exploring preclinical candidates that modulate other hormone pathways implicated in cardiometabolic and fibrotic disorders. Through partnerships with contract research organizations and regulatory agencies, the company aims to expand its pipeline and ultimately deliver new treatment options for patients suffering from metabolic and liver diseases worldwide.

Key Stats

• Today's Range: $54.37 to $54.83
• 50-Day Range: $53.91 to $54.69
• 52-Week Range: $37.28 to $57.35
• Volume: 15.31 million shs
• Average Volume: 1.86 million shs
• Market Capitalization: $4.50 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $60.80
• Consensus Rating: Hold

Akero Therapeutics Stock Analysis - MarketRank™

Akero Therapeutics scored higher than 7% of companies evaluated by MarketBeat, and ranked 831st out of 851 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.0 / 5
• Analyst Rating: Hold

Consensus Rating

Akero Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.10, and is based on no strong buy ratings, 2 buy ratings, 7 hold ratings, and 1 sell rating.

Upside Potential

Akero Therapeutics has a consensus price target of $60.80, representing about 11.3% upside from its current price of $54.65.

Amount of Analyst Coverage

Akero Therapeutics has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Akero Therapeutics are expected to decrease in the coming year, from ($3.99) to ($4.52) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Akero Therapeutics is -28.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Akero Therapeutics is -28.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Akero Therapeutics has a P/B Ratio of 5.08. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for AKRO.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Akero Therapeutics does not currently pay a dividend.

Dividend Growth

Akero Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

MarketBeat Follows

1 people have added Akero Therapeutics to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.3 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Akero Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

7.07% of the stock of Akero Therapeutics is held by insiders.

Percentage Held by Institutions

Akero Therapeutics has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 11/07/2025
• Today: 5/19/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:AKRO
• CIK: 1744659
• Web: www.akerotx.com
• Phone: (650) 487-6488
• Fax: N/A
• Employees: 30
• Year Founded: 2017

Price Target and Rating

• Average Price Target for Akero Therapeutics: $60.80
• High Price Target: $76.00
• Low Price Target: $54.00
• Potential Upside/Downside: +11.3%
• Consensus Rating: Hold
• Rating Score (0-4): 2.10
• Research Coverage: 10 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.94)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$252.06 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -15.86%
• Return on Assets: -14.78%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 15.84
• Quick Ratio: 15.83

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $10.75 per share
• Price / Book: 5.08

Miscellaneous

• Outstanding Shares: 82,320,000
• Free Float: 76,504,000
• Market Cap: $4.50 billion
• Optionable: Optionable
• Beta: -0.40